Innovotech Inc.

Innovotech Inc.

December 18, 2007 12:33 ET

Innovotech Sets Stage for Growth With Move to New Facility

EDMONTON, ALBERTA--(Marketwire - Dec. 18, 2007) - Effective December 1, 2007, Innovotech (TSX VENTURE:IOT) has relocated to a new laboratory and corporate office in Edmonton Research Park. The 3200 square foot facility will enable Innovotech to further advance development of its two lead products; Agress™, a novel agricultural seed treatment, and bioFILM PA™, a breakthrough in diagnostic susceptibility testing. It will also enable the company to expand its work with anaerobic bacteria and fungi, as well as conducting research protocols under Good Laboratory Practice (GLP) conditions. "This is a significant milestone on our company's history and will support the growth that the company anticipates over the short-term" stated Ken Boutilier, President and COO of Innovotech. "We will benefit substantially from being in close proximity to the over 50 biotechnology companies who are residents of Edmonton Research Park".

"Innovotech is one of the most promising biotechnology companies in the province," says Ron Gilbertson, president and CEO of Edmonton Economic Development Corp (EEDC). "We're pleased to be able to accommodate Innovotech in EEDC's new Biotech Business Development Centre which will be completed in the spring of 2008."

About Innovotech Inc:

Innovotech is a product development company focusing on the development of solutions to medical, agricultural and industrial problems caused by microbial biofilms. Biofilms are protected communities of microorganisms which are very common and very difficult to treat due to their inherent resistance. They have been implicated in a host of devastating infections in agriculture, human health and industry. No diagnostics or antibiotics are currently approved for use in infections involving biofilms.

The TSX Venture Exchange does not accept responsibility for the adequacy or accuracy of this release.

Contact Information